Browse the latest research summaries in the field of regenerative medicine for spinal cord injury patients and caregivers.
Showing 321-330 of 2,298 results
Mediators of Inflammation, 2015 • March 9, 2015
This review discusses the inflammatory responses after nervous system trauma, comparing CNS and PNS inflammation regarding magnitude, cell types, and effector molecules. In SCI, secondary damage invol...
KEY FINDING: Neutrophils, initially linked to deleterious effects in CNS trauma due to the release of proinflammatory cytokines, may also have proregenerative functions.
Cell Cycle, 2015 • July 15, 2015
The study demonstrates that nestin-expressing HAP stem cells, located in the hair follicle, can differentiate into beating cardiac muscle cells in vitro. The upper part of the hair follicle shows the ...
KEY FINDING: HAP stem cells from mouse vibrissa hair follicles can differentiate into beating cardiac muscle cells.
Molecular and Cellular Therapies, 2014 • May 1, 2014
The review highlights the initial eagerness for stem cell therapies for nervous system disorders, which has now been tempered by skepticism due to premature clinical trials and modest benefits. Basic ...
KEY FINDING: The adult central nervous system is generally resistant to regeneration, posing unique challenges for stem cell therapies.
Stem Cells International, 2015 • December 14, 2015
Spinal cord injury (SCI) is a central nervous system- (CNS-) related disorder for which there is yet no successful treatment. The roles of both cell- and biomaterial-based therapies as single therapeu...
KEY FINDING: Stem cells from different origins have been tested for their ability to stimulate nerve regeneration and restore the neuronal circuitry when integrated in the injured site.
BioMed Research International, 2015 • June 25, 2015
This review summarizes the characteristics of OPCs and their roles in SCI, focusing on remyelination and glial scar formation. The review discusses recent progress in OPC transplantation research and ...
KEY FINDING: Mature oligodendrocytes, responsible for myelination in the CNS, are highly susceptible to damage after SCI, leading to their loss.
BioMed Research International, 2015 • July 22, 2015
This review comprehensively analyzes the complex challenges of neurorestoration after spinal cord injury (SCI) and explores promising biomaterial approaches to overcome biological obstacles. It highl...
KEY FINDING: The postinjury environment of the spinal cord is hostile to regenerative processes due to molecular changes, inflammation, and the creation of a hypoxic environment. This leads to reactive astrogliosis, forming a chemophysical barrier that inhibits regenerative activity.
Neural Plasticity, 2015 • July 2, 2015
This study investigated the potential of combining Schwann cell (SC) transplantation with putrescine supplementation to improve spinal cord injury (SCI) repair in rats. The researchers hypothesized th...
KEY FINDING: Delayed putrescine supplementation significantly increased the size of the SC implant, suggesting enhanced survival or proliferation of the implanted cells.
Neural Plasticity, 2015 • June 7, 2015
This study investigated the effects of combining predegenerated peripheral nerve (PPN) and bone marrow stromal cells (BMSCs) transplantation on axonal regrowth, remyelination, and locomotor function i...
KEY FINDING: The combined transplantation of PPN and BMSCs resulted in greater axonal regrowth and remyelination compared to controls, as evidenced by increased expression of GAP-43, neuritin, and myelin basic protein.
Regeneration, 2014 • September 3, 2014
This study compares the early transcriptional response of iris to lentectomy between young and old axolotl larvae that differed in regeneration competence. The many highly differentially expressed gen...
KEY FINDING: Over 3700 genes were identified as differentially expressed between young (7 days post-hatching) and old (3 months post-hatching) axolotl larvae.
Biomedicines, 2014 • October 31, 2014
HGF was molecularly cloned as a growth factor for hepatocytes. The scatter factor, originally identified as a fibroblast-derived cell motility factor for epithelial cells, was shown to be an identical...
KEY FINDING: The intravenous/systemic administration of recombinant HGF protein has been well tolerated in phase I/II clinical trials.